Free Trial

Blueprint Medicines (BPMC) Stock Price, News & Analysis

-1.73 (-1.66%)
(As of 11:57 AM ET)
Today's Range
50-Day Range
52-Week Range
113,892 shs
Average Volume
745,358 shs
Market Capitalization
$6.42 billion
P/E Ratio
Dividend Yield
Price Target

Blueprint Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
1.5% Downside
$102.65 Price Target
Short Interest
7.25% of Shares Sold Short
Dividend Strength
News Sentiment
0.64mentions of Blueprint Medicines in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$9.55 M Sold Last Quarter
Proj. Earnings Growth
From ($5.15) to ($2.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.67 out of 5 stars

Medical Sector

847th out of 918 stocks

Pharmaceutical Preparations Industry

393rd out of 425 stocks

BPMC stock logo

About Blueprint Medicines Stock (NASDAQ:BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BPMC Stock Price History

BPMC Stock News Headlines

Unveiling 18 Analyst Insights On Blueprint Medicines
Q1 2024 Blueprint Medicines Corp Earnings Call
Rubrik to debut on NYSE, IPO priced at $32 per share
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
17 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$249.38 million
Book Value
$2.15 per share


Free Float
Market Cap
$6.53 billion

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

BPMC Stock Analysis - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 sell ratings, 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price target for 2024?

17 brokerages have issued 12-month price targets for Blueprint Medicines' stock. Their BPMC share price targets range from $43.00 to $168.00. On average, they predict the company's stock price to reach $102.65 in the next twelve months. This suggests that the stock has a possible downside of 1.5%.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2024?

Blueprint Medicines' stock was trading at $92.24 at the beginning of 2024. Since then, BPMC stock has increased by 13.0% and is now trading at $104.26.
View the best growth stocks for 2024 here

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our BPMC earnings forecast

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) posted its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.04) by $0.22. The biotechnology company had revenue of $71.96 million for the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 193.48% and a negative net margin of 102.15%. Blueprint Medicines's revenue was up 85.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.65) earnings per share.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.31%), Price T Rowe Associates Inc. MD (10.21%), William Blair Investment Management LLC (2.79%), Lord Abbett & CO. LLC (2.15%), Hood River Capital Management LLC (0.77%) and Jane Street Group LLC (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain.
View institutional ownership trends

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPMC) was last updated on 5/21/2024 by Staff

From Our Partners